Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dalbavancin versus vancomycin/linezolid for acute bacterial skin and skin structure infections
2010-024042-30Phase 3Completed
- Sponsor
- Durata Therapeutics
- Start
- Jan 2012
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI) and Staphylococcus aureus infection (2 arms), sponsored by Durata Therapeutics. Primary endpoint: Clinical response at 48-72 hours post study drug initiation. Started Jan 2012; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)Staphylococcus aureus infection
Beyond the preview
Go deeper on 2010-024042-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024042-30.